FIELD: medicine.
SUBSTANCE: methods are suggested for treating neovascular age-related macular degeneration of nAMD in a mammal, comprising administering to a mammal three separate doses of an anti-VEGF antibody, comprising a sequence of SEQ ID NO: 3, with four-week intervals.
EFFECT: presented group of inventions provides effective treatment of eye diseases.
14 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF EYE DISEASES | 2015 |
|
RU2771900C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| USE OF SIROLIMUS FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA | 2017 |
|
RU2765728C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| METHOD FOR PREDICTING RESPONSE TO REPEATED ANTI-VEGF THERAPY IN CHOROIDAL NEOVASCULARIZATION IN AMD | 2022 |
|
RU2788971C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
| METHOD FOR THE TREATMENT OF ACTIVE CHOROIDAL NEOVASCULAR MEMBRANES OF EXTRAFOVEAL LOCALIZATION | 2022 |
|
RU2777739C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF SUBRETINAL FIBROSIS IN PATIENTS WITH EXUDATIVE FORM OF AGE-RELATED MACULAR DEGENERATION GIVEN ANTI-VEGF THERAPY | 2022 |
|
RU2793419C1 |
